Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

The EMA has recommended label expansions for Inaqovi, Opdivo, and Venclyxto, broadening treatment options in AML, Hodgkin lymphoma, and CLL.

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

In the SEQUOIA trial, the BTK inhibitor zanubrutinib (Brukinsa) was delivered as a continuous dose in frontline chronic ...

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite ...

The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and ...

A cancer diagnosis hits like a thunderbolt, changing lives instantly and profoundly. Victor Gonzalez, senior director of patient programs and support services at The Lymphoma Research Foundation, ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

Please provide your email address to receive an email when new articles are posted on . 61% of patients with heavily pretreated CLL responded to single-agent epcoritamab therapy. Researchers intend to ...

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...